226 reports of this reaction
3.4% of all CALCIUM POLYCARBOPHIL reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for CALCIUM POLYCARBOPHIL, manufactured by Aurobindo Pharma Limited. There are 226 FDA adverse event reports linking CALCIUM POLYCARBOPHIL to FATIGUE. This represents approximately 3.4% of all 6,699 adverse event reports for this drug.
Patients taking CALCIUM POLYCARBOPHIL who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among CALCIUM POLYCARBOPHIL users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for CALCIUM POLYCARBOPHIL:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 226 FDA reports for CALCIUM POLYCARBOPHIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.4% of all adverse event reports for CALCIUM POLYCARBOPHIL, making it one of the most commonly reported side effect.
If you experience fatigue while taking CALCIUM POLYCARBOPHIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.